- NZ$8.97m
- NZ$7.71m
- NZ$2.43m
Brief: Truscreen Group Says Coga Trial Validates Superiority Of Truscreen Cervical Cancer Screening Method
Issue of Options - Capital Change Notice
Brief: Truscreen Group Says Achieved National Pricing Approval In China
TruScreen Achieves Significant Milestones with Distributors
Issue of Options - Capital Change Notice
Change of Directors Interest Notice X 2
TruScreen Makes Progress in Key Markets Worldwide
Half Year Accounts
PRE_NR Ends: 10:06:14
TruScreen Device - Milestones Achieved on Growth Strategy
PRE_NR Ends: 11:14:17
Trial Results Highlight Efficacy of TruScreen Technology
PRE_NR Ends: 10:08:32
Change of Director's Interest Notice
Recording of Annual Shareholder Meeting
Results of Meeting
Annual Shareholder Meeting Presentation
PRE_NR Ends: 08:44:27
PRE_NR Ends: 09:58:42